reagin
antipolyvalent
bispecific
-zumab
soravtansine
countercorrelated
antiantibody
zanolimumab
idiospecific
polyantibody
Ab
mapatumumab
intrabody
zolimomab
oportuzumab monatox
sulesomab
conatumumab
durvalumab
biciromab
alacizumab
-axo-
fontolizumab
antiidiotypic
heteroclitic
polyvalent
evolocumab
-ab
ocrelizumab
ipilimumab
lucatumumab
brentuximab
patritumab
carlumab
immunospecific
agonistic monoclonal antibody
antigenomic
tigatuzumab
oleclumab
immunoprecipitant
naptumomab estafenatox
antinucleosome
panitumumab
cedelizumab
dacetuzumab
nofetumomab
presentation
drozitumab
-a-
tenatumomab
immunoprobe